Prevention of chronic GVHD

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 2, 2008, Pages 259-270

  Lee, Jong Wook ^a   Joachim Deeg, H ^b,c  

^a The Catholic University of Korea   (South Korea)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

acute GVHD; Campath; PBPCs; thymoglobulin

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 7; MELPHALAN; METHOTREXATE; MINOR HISTOCOMPATIBILITY ANTIGEN; PLACEBO; RITUXIMAB; THALIDOMIDE; THYMOCYTE ANTIBODY; THYMOPOIETIN;

ACUTE GRAFT VERSUS HOST DISEASE; AGE; ANTIGEN PRESENTING CELL; APLASTIC ANEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; STEM CELL MOBILIZATION; SURVIVAL RATE; T CELL DEPLETION;

CHRONIC DISEASE; DONOR SELECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION;

EID: 44049103664     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.02.010     Document Type: Review

References (73)

1. Duell T., Van Lint M.T., Ljungman P., et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. Annals of Internal Medicine 126 (1997) 184-192
2. Deeg H.J., Leisenring W., Storb R., et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 91 (1998) 3637-3645
3. Flowers MED, Deeg HJ. Chronic graft-versus-host disease. In: Treleaven J, Barrett AJ, editors. Practical stem cell transplantation. Edinburgh, UK: Elsevier Ltd. p. 9999, in press.
4. Lorenz E., Uphoff D., Reid T.R., et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. Journal of the National Cancer Institute 12 (1951) 197-201
5. Elkins W.L. Cellular immunology and the pathogenesis of graft versus host reactions. [review]. Progress in Allergy 15 (1971) 78-187
6. van Bekkum D.W., and de Vries M.J. Radiation chimaeras (1967), Logos Press Limited, London
7. Billingham R.E. The biology of graft-versus-host reactions. The Harvey Lectures (1966), Academic Press, New York p. 21-78
8. Mathé G., Jammet H., Pendic B., et al. Transfusions et greffes de moelle osseuse homologue chez des humains irradiés a haute dose accidentellement. Revue française d'études cliniques et biologiques IV (1959) 226-238
9. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
10. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
11. Mielcarek M., Burroughs L., Leisenring W., et al. Prognostic relevance of 'early-onset' graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. British Journal of Haematology 129 (2005) 381-391
12. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation 11 (2005) 945-956
13. Hess A.D., and Jones R.J. Autologous graft-versus-host disease. In: Thomas E.D., Blume K.G., and Forman S.J. (Eds). Hematopoietic cell transplantation. 2nd ed. (1999), Blackwell Science, Boston 342-348
14. Storb R., Prentice R.L., Buckner C.D., et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. The New England Journal of Medicine 308 (1983) 302-307
15. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. Journal of Clinical Oncology 19 (2001) 3685-3691
16. Bensinger W., Martin P., Clift R., et al. A prospective, randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies. Blood 94 Suppl. 1 (1999) 368a #1637
17. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98 (2001) 3221-3227
18. Wagner J.E., Barker J.N., Defor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
19. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Seminars in Hematology 28 (1991) 250-259
20. Remberger M., Aschan J., Lonnqvist B., et al. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. European Journal of Haematology 66 (2001) 50-56
21. Randolph S.S.B., Gooley T.A., Warren E.H., et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic cell transplants. Blood 103 (2004) 347-352
22. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105 (2005) 2973-2978
23. Holmes J.A., and Whittaker J.A. Histocompatibility antigen DR4 is associated with chronic graft-versus-host disease in the south Wales population. British Journal of Haematology 73 (1989) 424
24. Pawelec G., Muller C.A., Haen M., et al. Chronic graft-versus-host disease and HLA-DR4 in the southern German population. British Journal of Haematology 75 (1990) 295-296
25. Kim H.J., Park S.J., Im H.W., et al. The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea. International Journal of Hematology 76 (2002) 267-271
26. Ho V.T., Mirza N.Q., del Junco D., et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplantation 32 (2003) 771-775
27. Ringden O., Paulin T., Lonnqvist B., et al. An analysis of factors predisposing to chronic graft-versus-host disease. Experimental Hematology 13 (1985) 1062-1067
28. Jenkins M.K., Schwartz R.H., and Pardoll D.M. Effects of cyclosporine A on T cell development and clonal deletion. Science 241 (1988) 1655-1658
29. Sakoda Y., Hashimoto D., Asakura S., et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 109 (2007) 1756-1764
30. Zhang C., Todorov I., Zhang Z., et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 107 (2006) 2993-3001 9
31. Kansu E. The pathophysiology of chronic graft-versus-host disease. [review]. International Journal of Hematology 79 (2004) 209-215
32. Alpdogan O., Schmaltz C., Muriglan S.J., et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98 (2001) 2256-2265
33. Alpdogan O., Muriglan S.J., Eng J.M., et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. The Journal of Clinical Investigation 112 (2003) 1095-1107
34. Sinha M.L., Fry T.J., Fowler D.H., et al. Interleukin 7 worsens graft-versus-host disease. Blood 100 (2002) 2642-2649
35. Chung B., Dudl E., Toyama A., et al. IL-7 is necessary for induction of experimental graft-versus-host disease (GVHD). Blood 102 Part 1 (2003) 149a #514
36. Weinberg K., Blazar B.R., Wagner J.E., et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97 (2001) 1458-1466
37. In: Ferrara J.L.M., Cooke K.R., and Deeg H.J. (Eds). Graft-versus-host disease (2005), Marcel Dekker, New York, NY
38. Seggewiss R., and Einsele H. Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation. [review]. Seminars in Hematology 44 (2007) 203-211
39. Lee S.J. New approaches for preventing and treating chronic graft-versus-host disease. [review]. Blood 105 (2005) 4200-4206
40. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
41. Chan G.W., Foss F.M., Klein A.K., et al. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biology of Blood and Marrow Transplantation 9 (2003) 753-759
42. Blume K.G., Beutler E., Bross K.J., et al. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. The New England Journal of Medicine 302 (1980) 1041-1046
43. Ringdén O., Persson U., Gunnar S., et al. Early diagnosis and treatment of acute human graft-versus-host disease. Transplantation Proceedings 15 (1983) 1490-1494
44. Deeg H.J., Lin D., Leisenring W., et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 89 (1997) 3880-3887
45. Chao N.J., Parker P.M., Niland J.C., et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biology of Blood and Marrow Transplantation 2 (1996) 86-92
46. Atkinson K., Storb R., Ochs H.D., et al. Thymus transplantation after allogeneic bone marrow graft to prevent chronic graft-versus-host disease in humans. Transplantation 33 (1982) 168-173
47. Atkinson K., Incefy G.S., Storb R., et al. Low serum thymic hormone levels in patients with chronic graft-versus-host disease. Blood 59 (1982) 1073-1077
48. Sokos D.R., Berger M., and Lazarus H.M. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 8 (2002) 117-130
49. Kansu E., Gooley T., Flowers M.E.D., et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. [brief report]. Blood 98 (2001) 3868-3870
50. Soiffer R.J., and Martin P. T-cell depletion of allogeneic hematopoietic stem cell grafts. In: Atkinson K., Champlin R., Ritz J., et al. (Eds). Clinical bone marrow and blood stem cell transplantation. 3rd ed. (2004), Cambridge University Press, Cambridge, UK 416-425
51. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. The Lancet 366 (2005) 733-741
52. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
53. Hale G., Zhang M.J., Bunjes D., et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92 (1998) 4581-4590
54. Barge R.M., Starrenburg C.W., Falkenburg J.H., et al. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath 'in the bag' as T-cell depletion: the Leiden experience. Bone Marrow Transplantation 37 (2006) 1129-1134
55. Soiffer R.J., Weller E., Alyea E.P., et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. Journal of Clinical Oncology 19 (2001) 1152-1159 [erratum appears in J Clin Oncol 2001 May 1;19(9):2583.]
56. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
57. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation 12 (2006) 560-565
58. Russell J.A., Duggan P., Chaudhry A.M., et al. Low dose antithymocyte globulin incorporated into GVHD prophylaxis for matched related donor stem cell transplantation results in low morbidity and no mortality from acute GVHD. Blood 98 Suppl. 1 (2001) 661a #2773
59. Remberger M., Svahn B.M., Mattsson J., et al. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 78 (2004) 122-127
60. Remberger M., Svahn B.M., Hentschke P., et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplantation 24 (1999) 823-830
61. Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biology of Blood and Marrow Transplantation 12 (2006) 573-584
62. Schetelig J., Bornhauser M., Kiehl M., et al. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation - a retrospective analysis. Bone Marrow Transplantation 33 (2004) 483-490
63. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biology of Blood and Marrow Transplantation 8 (2002) 468-476
64. Lopez M., Clarkson M.R., Albin M., et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+ CD25+ Foxp3+ regulatory T cells. Journal of the American Society of Nephrology 17 (2006) 2844-2853
65. Shulman H.M., and Sullivan K.M. Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation. In: Cruse J., and Lewis Jr. R.E. (Eds). Cellular aspects of autoimmunity. Concepts in immunopathology (1988), S. Karger, Basel 141-165
66. Maury S., Mary J.Y., Rabian C., et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. British Journal of Haematology 115 (2001) 630-641
67. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006) 756-762
68. Kim J., Choi W.S., La S., et al. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood 105 (2005) 2206-2213
69. Sasaki M., Hasegawa H., Kohno M., et al. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. Journal of Immunology (Baltimore, Md.: 1950) 170 (2003) 588-596
70. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104 (2004) 3501-3506
71. Akpek G., Lee S.J., Flowers M.E., et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multi-center study. Blood 102 (2003) 802-809
72. Lee S.J., Vogelsang G., and Flowers M.E.D. Chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 9 (2003) 215-233
73. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biology of Blood and Marrow Transplantation 12 (2006) 375-396